Treating heart failure by targeting fat metabolism

Neon heart
Ohio State University scientists found that normalizing acyl-CoA helps reduce toxic fats that can cause heart failure. (Connor Wells/Unsplash)

By burning fats and glucose, our hearts get the energy necessary to function well. Scientists at Ohio State University have identified a compound that's key in fat metabolism but that diminishes when the heart becomes stressed. Restoring it could reduce the risk of heart failure, they found.

Before any physical signs or symptoms of heart failure emerge, chronically stressed cardiac cells undergo changes to adapt, but the adjustments don’t necessarily make things better, said Doug Lewandowski, Ph.D., an Ohio State researcher who focuses on cardiac metabolism, in a statement.

Lewandowski’s team discovered that deficiencies of a reactive fat compound called acyl-CoA disrupt the heart’s energy production cycle, leading to toxic fat accumulation that impairs its ability to function and pump properly. The researchers examined mouse models of heart failure, as well as human heart tissue obtained from patients before and after left ventricular assist device (LVAD) implantation. They found that acyl-CoA is nearly 60% lower in troubled hearts compared to normal ones. They published their observations in the journal Circulation.


Lipid-based Formulations for Early Stage Clinical Trials

Liquid-filled capsule technology has a proven record for addressing complex API formulation challenges, but also offers a simple and effective pathway to the clinic. Register now to learn more about lipid-based formulations.

An enzyme called acyl-CoA synthetase (ACSL1) catalyzes the uptake and activation of long-chain fatty acids, a process that creates acyl-CoA. The team tested mice that overexpress the ACSL1-encoding gene by exposing them to stress conditions. The mice made normal levels of acyl-CoA, fatty acid trafficking was improved, and heart failure risk was reduced or delayed, the team reported.

“By maintaining this fat compound, acyl-CoA, the hearts retained their ability to burn fat and generate energy. Importantly, overexpression of ACSL1 also reduced toxic fats, normalized cell function and reduced the progressive loss of function in the enlarged mouse hearts,” Lewandowski said.

In human heart tissues, the scientists observed that levels of acyl-CoA returned to normal in post-LVAD samples. That makes sense: When the failing heart has extra help from the pump device, it doesn’t have to work as hard under stress.

RELATED: Repairing heart damage by targeting the stress response

Various new targets that could help tackle heart diseases have come to light lately. Researchers at Imperial College London pinpointed a protein called MAP4K4, which sends stress signals during cardiac arrest that eventually cause heart damage. A team at the Scripps Research Institute identified the GPR68 protein as a potential drug target that can help dilate blood vessels and keep the heart healthy.

Lewandowski's team plans to examine how increasing acyl-CoA levels leads to heart protection, and they hope to use advanced imaging to track fat metabolism in patients’ hearts. Ultimately “targeting the normalization of acyl-CoA through gene or drug therapy or, potentially, dietary protocols,” could open new possibilities to prevent or mitigate heart failure, Lewandowski said.

Suggested Articles

A new clinical hold is the latest setback for Solid Biosciences and the development of its gene therapy for Duchenne muscular dystrophy.

VBI's Sci-B-Vac protected twice as many people than GSK's Engerix-B did after the second dose.

The notice comes weeks after Amgen revealed it was retreating from its East Coast neuroscience operations.